Decade-long trends in prostate cancer incidence and mortality in Poland, 1999–2012
More details
Hide details
Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Center for Prostate Disease Research, Rockville, MD, USA
Department. of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
Jennifer Cullen   

Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD, 20852, USA.
Submission date: 2017-02-22
Acceptance date: 2017-05-02
Online publication date: 2018-02-23
Publication date: 2019-11-16
Pol. Ann. Med. 2018;25(1):56–61
In Poland, prostate cancer is the second most common cancer and third leading cause of cancer death among men. Understanding trends in prostate cancer incidence and mortality can inform efforts for prostate cancer prevention and control, yet information on national trends is lacking.

This study examined temporal trends in prostate cancer incidence and mortality in Poland for the years 1999–2012.

Material and methods:
Data on prostate cancer cases and deaths in Poland were provided by the Polish National Cancer Registry (PNCR). For each year, age-standardized incidence and mortality rates were calculated overall, as well as for each vovoideship, urban and rural regions, and age category.

Results and discussion:
The overall standardized incidence rate in Poland was found to double during this time period, from 17.39 cases per 100,000 person-years in 1999, to 36.12 in 2012. In contrast, standardized mortality rates remained stable, with 11.89 deaths per 100,000 person-years in 1999 and 12.41 deaths per 100,000 person-years in 2012. Standardized incidence and mortality varied by vovoideship. Standardized incidence but not mortality was higher in urban regions.

This study demonstrates the utility of using PNCR data for cancer epidemiologic research and identifies trends in prostate cancer incidence and mortality that require further inquiry

We would like to thank George W. Handy, Activity for Innovation and Economic Growth, for forging the collaboration between this team of researchers from the United States and Poland, and for his support throughout the course of this project.
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092.
Wojciechowska U, Didkowska J, Zatonski W. Cancer in Poland in 2012. Warsaw: Polish National Cancer Registry, Department of Epidemiology and Cancer Prevention; 2014.
Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164–1187.
Capocaccia R, Colonna M, Corazziari I, et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol. 2002;13(6):831–839.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):23–34.
Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, et al. Cancer epidemiology in Central, South and Eastern European countries. Croat Med J. 2011;52(4):478–487.
Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol. 2011;60(1):1–15.
Doll R, Payne P, Waterhouse JAH, eds. Cancer Incidence in Five Continents. Vol. 1. Geneva: Union Internationale Contre le Cancer; 1966.
Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950–57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. 2nd Ed. Boston: PWS–Kent; 1988.
Mottet N, Bastian PJ, Bellmunt J, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on Prostate Cancer. Uroweb: European Association of Urology; 2014.
Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.
Ministry of Health. Establishing and implementation of an early detection program for urogenital cancer among working men aged 45 years and over (45+), focused on preventing professional deactivation (concerning specifically men employed in professions related to high urogenital cancer risk). Accessed: 16.02.2018 [in Polish].
Fogleman AJ, Mueller GS, Jenkins WD. Does where you live play an important role in cancer incidence in the U.S.? Am J Cancer Res. 2015;5(7):2314–2319.
Di Francesco S, Tenaglia RL. Obesity, diabetes and aggressive prostate cancer hormone-naive at initial diagnosis. Cent European J Urol. 2014;66(4):423–427.
Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2012;23(5):1325–1334.
Didkowska J, Wojciechowska U, Zatonski W. Prediction of cancer incidence and mortality in Poland up to the year 2025. Warszawa: Centrum Onkologii. Instytut M. Skłodowskiej-Curie; 2009.